Under the Paperwork Reduction Act of 1995, no persons are required to re

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10811593		
Filing Date		2004-03-29		
First Named Inventor	Muhammad Anzar			
Art Unit		1651		
Examiner Name	Tiffany M. Gough			
Attorney Docket Number		MTC 2002.1 37-21(53264)B		

					U.S.I	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue E	Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1									
If you wis	h to a	i dd additional U.S. Patei	nt citatio	n inform	ation pl	ease click the	Add button.	_	Add	
			U.S.P	ATENT	APPLIC	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant		Relev	s,Columns,Lines when ant Passages or Rele es Appear	
	1									
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	lease click the Ad	d butto	n. Add	
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	+-
	1									
If you wis	h to a	dd additional Foreign P	atent Do	cument	citation	information pl	ease click the Add	button	Add	_
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove	
Examiner linitials* cite include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						Тs				

Application Number 10811593 Filing Date 2004-03-29 INFORMATION DISCLOSURE First Named Inventor Muhammad Anzar STATEMENT BY APPLICANT Art I Init 1651 (Not for submission under 37 CFR 1.99) Examiner Name Tiffany M. Gouch Attorney Docket Number MTC 2002.1 37-21(53264)B

EYAMINER SIGNATURE							
If you wish to add additional non-patent literature document citation information please click the Add button Add							
	3	Millipore Specially Media, IVF Protocol, http://www.speciallymedia.com/05Resources/Protocols/v/protocol.htm					
	2	SABEUR, K., et al., "Effects of Angiolensin II on the Acrosome Reaction in Equine Spermatozoa," 2000, J Reprod Fert, V120, pp 135-142					
	1	DE PALIW, M.C., et al., "Sperm Binding to Epithelial Oviduot Explaints in Bulls with Different Nonreturn Rates Investigated with a New in Vitro Modet," 2002, Biol Reprod., V67, pp 1073-1079					

Date Considered Examiner Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the inducation of the year of the reion of the Emperor must precede the serial number of the patent document Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10811593		
Filing Date		2004-03-29		
First Named Inventor	Muhammad Anzar			
Art Unit		1651		
Examiner Name	Tiffar	Fiffany M. Gough		
Attorney Docket Number		MTC 2002.1 37-21(53264)B		

CERTIFICATION STATEMENT

Please see 37	7 CFR 1.97 and	1.98 to make the	appropriate selection(s):
---------------	----------------	------------------	---------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 1.97(eVI.)

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(s)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- .7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Timothy B. McBnde/	Date (YYYY-MM-DD)	2006-07-28
Name/Drint	Timothy D. McDrido	Desistration Number	A7 781

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is foll field and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenan's Afford, U.S. Department of Commence, P. 0. Bot 1450, Alexandria, V.32.511.450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. 0. Box 1450, Alexandria, V.32.311.450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application port to public insepticines or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.